The pathogenesis of lupus nephritis (LN) is complicated, and diagnostic and treatment basis of lupus nephritis hasn’t been thoroughly illuminated by the clinicians. Notwithstanding the anti-dsDNA antibody and anti-Sm antibody are utilized as markers of systemic lupus erythematosus (SLE) in diagnostic criterion of American College of Rheumatology (ACR) and the Systemic Lupus International Collaborating Clinics (SLICC). According to the recent researches, anti-C1q, anti-nucleosome antibody (AnuA) and Connective Tissue Growth Factor (CTGF) also have rather high sensitivity towards SLE, especially LN, which means they play key roles in the occurrence of such disease as well. In addition, more and more researchers look into combined-detection based on double or multiple related autoantibodies, in order to get over the deficiency of low sensitivity for anti-Sm antibody. With the support of joint diagnostic basis, the patients will be provided a better diagnosis and a higher detection rate.